# CBA-1205

Source: https://onco.cc/drugs/cba-1205/  
OnCo record `cba-1205` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CBA-1205 is an experimental humanized afucosylated monoclonal antibody from Chiome Bioscience, in phase 1 trials for advanced solid tumours, hepatocellular carcinoma and melanoma and other cancers.

## Summary

CBA-1205 is a humanized afucosylated monoclonal antibody (ADCC enhanced) from Chiome Bioscience. A humanized, afucosylated antibody against DLK-1, made with enhanced antibody-dependent cellular cytotoxicity (ADCC). Its furthest stage is phase 1, for advanced solid tumours, hepatocellular carcinoma, melanoma and paediatric cancer. ClinicalTrials.gov registers it in one study linked below. Phase 1 first-in-human study NCT06636435 recruiting per ClinicalTrials.gov (study start June 2020, first posted October 2024). Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: CBA-1205
- Modality: Humanized afucosylated monoclonal antibody (ADCC enhanced)
- Mechanism: A humanized, afucosylated antibody against DLK-1, made with enhanced antibody-dependent cellular cytotoxicity (ADCC).

## Sources

- Chiome Bioscience: chiome.co.jp: https://www.chiome.co.jp/en/pipeline/
- Chiome Bioscience: chiome.co.jp: https://www.chiome.co.jp/en/pipeline/
- Chiome Bioscience: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT06636435
- ClinicalTrials.gov: trials of CBA-1205: https://clinicaltrials.gov/search?intr=CBA-1205

## Connected records

- cancers: [Childhood cancers (all types)](https://onco.cc/cancers/childhood-cancers/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Melanoma](https://onco.cc/cancers/melanoma/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Neuroblastoma (paediatric)](https://onco.cc/cancers/neuroblastoma/)
- companies: [Chiome Bioscience](https://onco.cc/companies/chiome-bioscience/)
- trials: [A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer](https://onco.cc/trials/nct06636435/)

---
JSON: https://onco.cc/api/v1/entities/cba-1205.json